References


22. American Biologics, Tijuana, Mexico, patient brochure, undated.


71. Batson, E., Senior Scientist, Department of Technology Assessment, American Medical Association, Chicago, IL, personal communication, December 1987.
77. “Biography of Dr. Hans A. Nieper,” mimeograph obtained from the A. Keith Brewer Science Library, Richland Center, WI, undated.
78. Bio-Medical Center, Information sheet on Hoxsey Therapy, typescript, undated.
88. Blue Cross and Blue Shield Association, “TEC Program,” unpublished mimeograph, Chicago, IL, undated.
94. Bott, V., Anthroposophical Medicine: Spiritual Science and the Art of Healing (New York, NY:


Briggs, B. E., Transcript of disciplinary action against him by Minnesota board, April 19, 1983.


Burlington, B., Food and Drug Administration, U.S. Department of Health and Human Services, Rock-


152. Cameron, E., Linus Pauling Institute of Science and Medicine, personal communication, July 1988.

153. Cameron, E., Linus Pauling Institute of Science and Medicine, letter, February 27, 1990.


165. Cancer Control Society, “Fact Sheet Taken From the Articles of Incorporation,” unpublished mimeograph, Los Angeles, CA, undated.
166. Cancer Control Society, form letter to individuals requesting information, Los Angeles, CA, undated.


220. Colonial Life and Accident Insurance Company, “Policy for Cancer and Other Specified Diseases” (Form HBDS), Columbia, SC, undated.
241. Cunniff, C., Medical Director, Blue Cross and Blue Shield of New Jersey, Newark, NJ, personal communication, September 1988.
References


277. Evans, M., Extending the Art of Healing. An Introduction to Anthroposophical Medicine, pamphlet, reprinted from “Work Arising From the Life of Rudolf Steiner,” Rudolf Steiner Press, undated.


284a. Federation of State Medical Boards of the United States, Inc., The Exchange (Ft. Worth, TX: Federation of State Medical Boards of the United States, 1987).


266 • Unconventional Cancer Treatments


305. Freimuth, V., University of Maryland, College Park, MD, personal communication, December 1987.


References .267

322. Genesis West (Division of Vitachem International Inc.), “Live Cell Therapy,” patient brochure, Redwood City, CA.
329. Gerson Institute, “Gerson Therapy Center Opens. When Cancer Becomes Incurable by Orthodox Methods, Perhaps Gerson Therapy is the Answer,” flyer, undated.


357. Goodspeed, R. B., Assistant Medical Director, Corporate Medical Division, CIGNA Corporation, Hartford, CT, personal communication, June 1988.


359. Greenberg, N. H., Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services, Memo to J.A.R. Mead, Acting Associate Director, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, November 1, 1983.


References


402. Hildenbrand, G., Gerson Institute, “Procedure and Criteria for Selection of Best Cases,” memo to Drs. Pelton, Ortuno, and Rogers, Gerson Institute, undated.


405. Hippocrates Health Institute, West Palm Beach, FL, brochure, undated.


442. In the Matter of the Complaint Against Ronald and Pamela McCaa and Delia Lighthouse, P.S. Docket


484. **Kohn, R., Managing Director, Advisory Services (Clinical & General) Limited, London, England, letter to M. Finotto, M.D., Farchemia SpA, Treviglio(BG), Italy, December 5, 1986.**


486. **Kossi, T., Vice President and General Counsel, MetPath Inc., letter to G. Solan, Office of Technology Assessment, U.S. Congress, March 30, 1989.**


499. **Kushi, Foundation, “Biography of Michio Kushi,” typescript, undated.**


512. **Ladas, H.S., “Antineoplastons in Cancer Patients with Five Year Followup,” *Townsend Letter for"
References


520. Lawrence Review of Natural Products, Chaparral, 5(8), August 1984.


540. Levi, J., Department of Oncology, Royal North Shore Hospital, Sydney, Australia, personal communication, July 1988.


553. Link, J., Chairman of the Board, IAT Patients’ Association, Kalamazoo, MI, personal communication, January 5, 1989.


557. Linus Pauling Institute of Science and Medicine, “General Recommendations for Thinking Large Amounts of Vitamin C,” mimeograph, Palo Alto, CA, undated.

558. Linus Pauling Institute of Science and Medicine, cover letter to information packet on vitamin C treatments for cancer, Palo Alto, CA, undated.


574. Manner, H., oral presentation in seminar held on September 25, 1987, King of Prussia, PA, videotape.


595. McGrady, P.M., Jr., Director, CANHELP, Port Ludlow, WA, personal communication, March 1987.


617. Miller, M., untitled typescript, obtained from Medical Research, Inc., Las Vegas, NV, undated.


625. **Mohs, F.E., Chemosurgery; Microscopically Controlled Surgery for Skin Cancer** (Springfield, IL: Charles C. Thomas, 1978).

626. **Moikeha, D.H., and Hokama, Y.**, “Effect of Crude *Tabebuia* Extracts In Vitro and In Vivo on Macrophages and Lewis Lung Carcinoma in C57B1/6J Mice,’ unpublished manuscript, Department of Pathology, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI. Presented to the Minority Biomedical Symposium, New Orleans, LA, April 1986.


637. Moore, E., Blue Cross and Blue Shield Association, Chicago, IL, personal communication, June 7, 1990.

638. Moore, G., Chief, Division of Surgical Oncology, Denver General Hospital, Denver, CO, personal communication, October 28, 1988.


641. Morris, L. C., Senior Vice President, Health Benefits Management, Blue Cross and Blue Shield Association, Chicago, IL, personal communication, June 1988.


References .279


726. Physicians Association for Anthroposophical Medicine, personal communication, March 24, 1990.


729. Portlock, C., Yale University School of Medicine, New Haven, CT, personal communication, May 1988.


757. Richards, E., Science and Technology Studies Department, University of Wollongong, Wollongong, Australia, personal communication, April 2, 1990.


References .281

780. **Schaffarzick,** R., Senior Vice-President and Medical Director, Blue Shield of California, San Francisco, CA, personal communication, September 1988.
786. **Schneider v. Revici,** 817 F.2d 987 (2nd Cir. 1987).
787. **Schneider,** A., program Administrator, Department of Technology Assessment, American Medical Association, Chicago, IL, personal communication, March 1988.
790. **Schultz,** R., Staff Attorney, Texas State Board of Medical Examiners, Austin, TX, personal communication, November 22, 1989.
805. Sikora, K., Professor of Clinical Oncology, Royal Postgraduate Medical School, University of London, letter, February 14, 1990.
815. Snyder, R., Executive Director, Payment Management, Blue Cross and Blue Shield Association, Chicago. IL, personal communication, August 1988.


Sullivan-Fowler, M., Medical Historian, Division of Library and Information Management, American Medical Association, Chicago, IL, personal communication, December 1987.


Tennenbaum, D., Manager, Medical Necessity Program, Blue Cross and Blue Shield Association, Chicago, IL, September 1988.


*Travel King, Inc.*, 86 F.T.C. 715 (1975).

Trombetta, L., Director of Public Information, Burzynski Research Institute, mailing addressed to “patients and friends,” typescript, February 8, 1990.


U.S. Congress, Office of Technology Assessment, *Assessing the Efficacy and Safety of Medical


Siccacell Therapy),” Import alert notice, number 66-03 revised, March 25, 1986.


911. United States v. Burzynski Cancer Research Institute, 829 F.2d 1124, (5th Cir. 1987).


917. United States v. Richardson, 588 F.2d 1235, (9th Cir. 1978).


920. United States v. Rutherford, 616 F.2d 455 (10th Cir. 1980).


928. Venditti, J.M., Chief, Drug Evaluation Branch, National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services, memorandum to Acting Director, Division of Cancer Treatment, National Cancer Institute, July 21, 1980, referring to NCI test #NSC B99979.


937. Washützl, J., Steiner, I., and Salzer, H., “Reaction of an 02/03 Mixture on Tumor Tissue and Health Tissue In Vitro,” typescript obtained from Medicinone International, undated.


References • 287

956. Wheeler, W.L., M.D., Secretary, Medical Society of the County of New York, letter to B. Lichello (S.J. Haught), National Enquirer, New York, April 23, 1958.
963. Winn, R., Chairman, Unorthodox Practices Committee, American Society for Clinical Oncology, Houston, TX, personal communication, October 14, 1987.


Zavertnick, J., “Analysis of Evidence Presented by Dr. Burton to the Legislators on IAT Therapy,” unpublished, December 9, 1981.


